XML 67 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended 209 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
Operating activities:        
Net loss $ (10,153) $ (13,186) $ (15,243) $ (276,888)
Adjustments to reconcile net loss to net cash used in operating activities:        
Accretion of interest on notes payable, net of amortization of debt premium       100
Amortization of investment premiums, net       (2,297)
Change in valuation of liabilities at fair value (1,120) (28) (609) (7,475)
Non-cash consideration associated with stock purchase agreement 98 423   521
Depreciation 70 60 241 12,685
Amortization of intangible assets       886
Fixed asset impairment       221
Unrealized foreign exchange losses       7,747
Deferred revenue       (98)
Compensation for warrants issued to non-employees       1,215
Gain on sale of patents (5,500)     (5,500)
Shares issued for IP rights       446
Loss (gain) on disposal of property, plant and equipment   (62) 1 38
Goodwill and intangibles impairment       7,934
Stock-based compensation 357 380 882 19,760
Provision for restructuring       1,779
Amortization of issuance costs of Preferred Ordinary 'C' shares       2,517
Transaction costs on sale of Economic Rights   33   33
Gain on termination of distribution agreements   (1,192)   (1,192)
Changes in operating assets and liabilities:        
Prepaid expenses and other assets (1,201) (239) 174 (1,498)
Accounts payable and other current liabilities (750) 1,768 577 (4,295)
Net cash used in operating activities (18,199) (12,043) (13,977) (243,361)
Investing activities:        
Purchase of ALIGN       (3,763)
Purchase of property, plant and equipment (208) (12) (6) (9,057)
Minimum royalty payments received from termination of ALIGN license agreement 396     396
Proceeds from sale of patents 5,500     5,500
Proceeds from sale of property, plant and equipment   62 5 225
Purchase of short-term investments on deposit, net of maturities       (156,657)
Cash proceeds from redemption of short term securities       162,729
Net cash (used in) provided by investing activities 5,688 50 (1) (627)
Financing activities:        
Payments of capital lease obligations       (3,719)
Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs       121,678
Proceeds from issuance of common stock and warrants, net of issuance costs 27,637 3,881 9,267 123,189
Proceeds from the exercise of stock options and warrants, net of issuance costs   94 3 267
Payment of preferred stock dividend (305)   (364) (2,203)
Repayment of government loan       (455)
Government loan received       414
Loan received from Cyclacel Group plc       9,103
Proceeds of committable loan notes issued from shareholders       8,883
Loans received from shareholders       1,645
Cash and cash equivalents assumed on stock purchase of Xcyte       17,915
Costs associated with stock purchase       (1,951)
Net cash provided by financing activities 27,332 3,975 8,906 274,766
Effect of exchange rate changes on cash and cash equivalents (87) (19) 26 368
Net increase (decrease) in cash and cash equivalents 14,734 (8,037) (5,046) 31,146
Cash and cash equivalents, beginning of period 16,412 24,449 29,495  
Cash and cash equivalents, end of period 31,146 16,412 24,449 31,146
Cash received during the period for:        
Interest 12 10 31 11,768
Taxes 970 565 685 19,742
Cash paid during the period for:        
Interest       (1,914)
Schedule of non-cash transactions:        
Acquisitions of equipment purchased through capital leases       3,470
Issuance of common shares in connection with license agreements       592
Issuance of Ordinary shares on conversion of bridging loan       1,638
Issuance of Preferred Ordinary 'C' shares on conversion of secured convertible loan notes and accrued interest       8,893
Issuance of Ordinary shares in lieu of cash bonus 181     345
Issuance of other long term payable on ALIGN acquisition       $ 1,122